SparingVision puts faith in Kali Stasi ahead of key trials

France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 

A seasoned physician-scientist with more than 30 years of ophthalmology experience, Dr Stasi is believed to possess the required strategic leadership and expertise in early and late-stage clinical development to successfully advance the company’s gene therapy programs through proof of concept, pivotal trials and toward commercialization. 

She succeeds Daniel Chung, who played a key role in advancing SparingVision’s assets to early-stage clinical development over the past five years.